Chemed Beats Earnings Estimates Again!

Chemed announced its third-quarter earnings for 2026, surpassing analyst expectations with earnings of $6.75 per share against an estimate of $6.39. This marks the third time in the last four quarters that Chemed has exceeded earnings per share (EPS) estimates. The company's revenues for the quarter reached $690.94 million, exceeding the consensus estimate by 1.60%. Year-to-date, Chemed shares have surged by 19.9%, significantly outperforming the S&P 500's 12.1% gain. Despite these robust results, Chemed's stock currently holds a Zacks Rank #4 (Sell), indicating an unfavorable trend in earnings estimate revisions. The company is expected to post current consensus EPS of $7.55 on revenues of $705.72 million for the upcoming quarter. Its industry, Medical - Outpatient and Home Healthcare, ranks in the bottom 36% of Zacks industries, suggesting potential headwinds.

Looking ahead, Chemed's future stock performance will likely depend on management's commentary regarding future earnings expectations during the upcoming earnings call. The current consensus EPS estimate for the full fiscal year is $25.43 on revenues of $2.72 billion. Investors are also keeping an eye on other companies in the same sector, such as Aveanna Healthcare (AVAH), which is expected to report its Q3 2026 results on November 12, with an anticipated quarterly EPS of $0.20 and revenues of $683.17 million.